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Brief Communication
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Abstract
Background: Despite descriptions of various cardiovascular manifestations in patients with
COVID-19, there is a paucity of reports of new onset brady-arrhythmias, and the clinical
implications of these events are unknown.
Methods: Seven patients presented with or developed severe brady-arrhythmias requiring
pacing support during the course of their COVID-19 illness over a six-week period of peak
COVID-19 incidence. A retrospective review of their presentations and clinical course was
performed.
Results: Symptomatic high degree heart block was present on initial presentation in 3 of 7
patients (43%), and 4 patients developed sinus arrest or paroxysmal high degree AV block.
No patients in this series demonstrated left ventricular systolic dysfunction or acute cardiac
injury, whereas all patients had elevated inflammatory markers. In some patients, bradyarrhythmias occurred prior to the onset of respiratory symptoms. Death from complications
of COVID-19 infection occurred in 57% (4/7) during the initial hospitalization, and in 71%
(5/7) within three months of presentation.
Conclusions: Despite management of bradycardia with temporary (3/7) or permanent
leadless pacemakers (4/7), there was a high rate of short-term morbidity and death due to
complications of COVID-19. The association between new-onset brady-arrhythmias and
poor outcomes may influence management strategies for acutely ill patients with COVID-19.
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Introduction
Various cardiovascular complications have been described in patients with
Coronavirus 2019 (COVID-19), and with it a concern for a higher mortality.1 Recent reports
have described acute cardiac injury,2,3 cardiogenic shock,3 electrocardiographic (ECG)
changes,1,4 right ventricular dysfunction,5 thromboembolic complications,6 and tachyarrhythmias.7 Ventricular arrhythmias have been reported as the first clinical manifestation of
COVID-19.8 However, reports of severe brady-arrhythmias have been rare, mostly anecdotal,
and likely under-reported.9 The clinical implications of new onset brady-arrhythmias in
patients with COVID-19 are unknown, and the approach to management is debatable without
understanding short- and long-term outcomes, and the risk to health care providers involved
with urgent invasive procedures.
Herein we report 7 cases of patients admitted to our health system in Suffolk County,
New York during the initial six-week period of peak COVID-19 incidence, who presented
with or developed severe brady-arrhythmias during hospitalization. The management
strategies and short-term outcomes including in-hospital mortality are described.

Methods
We included all patients with confirmed COVID-19 admitted March 15 - April 30,
2020, to two affiliated hospitals who required pacing support for severe bradycardia. Patients
were excluded if their bradycardia required only medication adjustment, was identified only
at the time of death, or if an alternate etiology of bradycardia was suspected. Clinical data
was obtained from the electronic medical record. All testing and treatment, including

This article is protected by copyright. All rights reserved.

4

permanent and temporary pacemaker implantations, were performed at the discretion of the
treating physicians.
The Northwell Health Institutional Review Board approved this case series as
minimal-risk research using data collected for routine clinical practice and waived the
requirement for informed consent. The initial characteristics of 5700 patients from Northwell
are presented elsewhere;2 this case series presents in-depth cardiac results not in that article.

Results
Between March 15 and April 30, 2020, seven patients with confirmed COVID-19 and
severe bradycardia requiring acute intervention were retrospectively identified. Demographic
and clinical characteristics of these patients are shown in Table 1. An overview of each
patient’s presentation and clinical course are presented in Table 2.
Symptomatic high degree heart block was present on initial presentation in 3 of 7
patients (43%); in two patients, respiratory symptoms developed later in their hospitalization
(despite chest radiography suggestive of viral pneumonia at presentation) and the diagnosis of
COVID-19 was made after permanent pacemaker implantation (Figure 1). Four patients
developed sinus arrest or paroxysmal high degree atrioventricular (AV) block lasting between
10-37 seconds documented on inpatient telemetry.
No patients in this series had preexisting cardiac disease. No significant QT
prolongation was noted at baseline or during hospitalizations, though preexisting conduction
disease was present in 3 patients. Echocardiography performed during hospitalization, or
within 6 months prior, revealed normal left ventricular systolic function in all patients (left
ventricular ejection fraction 67.5% ±14.3%). Severe pulmonary hypertension and/or right
This article is protected by copyright. All rights reserved.
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ventricular dysfunction was identified in two patients. There was no evidence of acute
coronary syndrome or documented thromboembolism. Respiratory symptoms and
radiographic evidence of viral pneumonia were ultimately present in all patients.
Laboratory findings demonstrated significantly elevated inflammatory markers in all
patients. No significant electrolyte or thyroid function abnormalities were observed. Cardiac
troponin levels (measured with the Roche troponin T assay) were normal in three patients
(≤0.01 ng/mL), not measured in two patients, and mildly elevated in two patients who both
had concomitant renal insufficiency: patient #1 had ESRD and peak troponin 0.23 ng/mL,
and patient #5 had a peak troponin of 0.17 ng/mL in the setting of acute renal failure and
peak creatinine >6 mg/dl) (Table 1). No patients demonstrated ischemic ECG changes apart
from bradycardia or conduction disturbances. Two patients received new rate-slowing
medication prior to the brady-arrhythmia events, however, this was not considered to be the
primary factor precipitating bradycardia in either case. Five patients received
hydroxychloroquine during their hospitalization, four prior to their first recorded bradycardia
episode.
Due to perceived life-threatening bradycardia, all patients received temporary (3/7) or
permanent pacemakers (4/7). One patient (patient #5) who received a temporary pacemaker
after the initial bradycardia event subsequently received a leadless pacemaker due to
recurrent bradycardia. In all five patients receiving permanent pacemakers, a leadless
pacemaker (Medtronic Micra®) was implanted. No operating staff involved in these
procedures subsequently developed COVID-19.
Mortality in this cohort was high, as 5/7 (71%) patients died within three months
following admission. Four of the seven patients (57%) died during the initial hospitalization,
occurring 17.3 +/- 12.5 days following admission and 8.3 +/- 10.7 days after the first
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identified brady-arrhythmia. All mortalities were considered complications of COVID-19
infection, including three patients with hypoxemic respiratory failure, and one who developed
fevers, lethargy and hypoglycemia prior to expiration, presumed to be due to COVID-19
sepsis. Another patient had a prolonged hospital course with multisystem organ failure
ultimately requiring tracheostomy and feeding tube placement, and suffered further
complications following discharge to a long-term care facility prompting withdrawal of
supportive care and subsequent expiration on day 90 following initial hospital admission. In
the two patients who survived, one had an acute stroke and the other had transient severe
encephalopathy during their hospitalizations.

Discussion
In this series of 7 patients with COVID-19 and severe brady-arrhythmias, short-term
mortality and morbidity was high, despite prompt management of bradycardia with pacing
support. All patients had elevation of inflammatory markers and multisystem organ
involvement, without acute cardiac injury or associated cardiomyopathy. In some patients,
brady-arrhythmias presented prior to the onset of respiratory symptoms.
The mechanism of cardiac involvement during COVID-19 remains speculative. Acute
bradycardia may be due to direct SARS-CoV-2 infiltration of myocardial cells and the
dedicated conduction system, aggravation of pre-existing conduction disease during acute
illness, pulmonary injury leading to hypoxia and secondary bradycardia, or collateral damage
from inflammatory system activation and cytokine storm.10 SARS-CoV-2 may also activate
the ACE2 receptor,10 as ACE2 expression has been demonstrated specifically in sino-atrial
nodal cells,11 and ACE2 overexpression has been associated with conduction disturbances.12
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In addition, the SARS-CoV virus causing the 2002 outbreak was associated with sinus
bradycardia in up to 15% of patients.10,13
Adverse effects of medications, including chloroquine and hydroxychloroquine, may
also contribute to conduction system dysfunction. Long-term chloroquine use has been shown
to increase Purkinje fiber refractory period and action potential duration, resulting in AV
nodal and infra-Hisian conduction disturbance,14 most commonly fascicular block.15 Five
patients in this series were treated with hydroxychloroquine, though this treatment preceded
the development of bradycardia in only four.
All patients received temporary or permanent pacing. A leadless pacemaker was
implanted in all patients clinically deemed to require permanent pacing. Leadless pacemaker
implantation may be an attractive option in patients with active COVID-19, as the risk of
cardiac and intravascular infection may be lower, and the risk of viral transmission to
operating staff may be mitigated by the percutaneous approach. However, despite pacing
support, outcomes were poor, with 4/7 patients dying during initial hospitalization, and 5/7
dying within three months due to complications of COVID-19.

Conclusion
Brady-arrhythmias may occur as part of the clinical course in patients with COVID19. In our experience, acute bradycardia was associated with elevation of inflammatory
markers and high short-term mortality rates, despite lack of co-existent cardiomyopathy or
acute cardiac injury. Management decisions and resource allocation should take into account
the potential for adverse outcomes regardless of invasive pacing support, as well as potential
risks to health care staff during intervention on these acutely ill patients.
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Figure Legend
Figure 1. A patient presenting with AV block and imaging findings consistent with
COVID-19 prior to development of pulmonary symptoms.
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A: Baseline ECG prior to admission. B: ECG on presentation demonstrating 3rd
degree AV block. C: CT on admission with incidental findings of ground-glass nodular
opacities in the lung apices. D and E: Chest X-ray from admission, and following leadless
pacemaker implant (arrow) showing progressive bilateral pulmonary infiltrates.
Table 1. Clinical Characteristics on Presentation

Parameter
a)

b)

Overall
(n=7)

DEMOGRAPHICS

Age (years)

64 ± 9.6

Male gender

42.9% (3)

Residential Care Facility Resident

28.6% (2)

Obese (BMI>30)

28.6% (2)

CARDIOVASCULAR RISK FACTORS
Hypertension

71.4% (5)

Hypercholesterolemia

14.3% (1)

Diabetes Mellitus

85.7% (6)

Hepatic disease/Cirrhosis

28.6% (2)

Cerebrovascular Disease / Stroke prior to admission

14.3% (1)

Chronic Kidney Disease

14.3% (1)
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BASELINE CONDUCTION DISEASE
RBBB

28.6% (2)

LBBB

0% (0)

LAHB + RBBB

14.3% (1)

First degree AVB

14.3% (1)

Prior Sinus Node Dysfunction

0% (0)

SYMPTOMS ON HOSPITAL PRESENTATION
Dyspnea

57.2% (4)

c)

Fever

57.2% (4)

d)

Chest Pain

28.6% (2)

e)

Dizziness

MEDICATIONS
Beta-blocker

42.9% (3)

28.6% (2)

ACE-Inhibitor or Angiotensin Receptor Blocker

14.3% (1)

Aspirin

28.6% (2)

Hydroxychloroquine

71.4% (5)

Actemra

28.6% (2)

Anakinra

14.3% (1)

Convalescent Plasma

14.3% (1)

LABORATORY VALUES
Troponin (n=5)
Initial

0.046±0.103

Peak

0.08±0.112

CRP (n=6)
Initial

15.3±16.1

Peak

22±13.8
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Ferritin (n=5)
Initial

1109±337

Peak

5017±6955

D-dimer (n=5)
Initial

2938±4085

Peak

7636±6986

AST
Initial

51±31

Peak

971±2276

ALT
Initial

31±9

Peak

540±1189

Potassium
Initial

4.6±0.8

Minimum

3.6±0.9

Peak

5.2±1.1

Magnesium
Initial

2.1±0.4

Minimum

1.9±0.5

Peak

2.6±0.6
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Table 2. Patient Specific Clinical Events and Outcomes

Presenting
Symptoms/
Diagnosis

Patient

f)

#
1

g)

#

Dizziness,
weakness,
acute CVA

Fall

Bradycard
ia Present
on
Admission

CHB

2

#3

#4

#5

Unilateral
facial droop,
abdominal pain

Dizziness,
fever, dyspnea,
pleuritic chest
pain

Myalgias,
cough, dyspnea
and pleuritic
chest pain

Interventio
n

(# of Days
After
Admission
)

(# of Days
after
Admission
)

1 degree
AV block

Brief dyspnea
with
pulmonary
infiltrates
found on CXR
day 21 of
hospitalization

CHB with
narrow
complex
escape
rhythm (0)

Leadless
pacemaker
implant (2)

Death (26)

RBBB,
LAFB

Fever and
hypoxia
starting day 2
of
hospitalization

CHB with
wide
complex
escape
rhythm (0)

Leadless
pacemaker
implant (0)

Death (6)

Leftward
axis only

Fever, cough
starting day 1
of
hospitalization

Sinus
bradycardia
and
intermittent
CHB with
junctional
escape
rhythm (15)

RBBB

Fever, chills,
cough, dyspnea
and pleuritic
chest pain on
presentation

Preexistin
g
Conductio
n
Disorder

st

CHB

None

2:1 AV
block

None

Outcome at
End of
Hospitalizati
on
(# of Days
after
Admission)

Bradycard
ia Event

None

COVID-19
Symptoms
(non-cardiac)

Myalgias,
cough,
dyspnea,
pleuritic chest
pain
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2:1 AV
block (0)

Sinus
pauses up
to 10
seconds
(30)

Temporary
pacemaker
(26)

Leadless
pacemaker
implant (2)

Semipermanent
pacemaker
implant
(34)
and
leadless
pacemaker
implant
(58)

Discharged
(40)
No permanent
pacing
required

Discharged
(15)
No permanent
pacing
required

Discharged to
long-term
acute care
facility (48)
Death due to
further
complications
(90)

15

#6

Myalgias,
cough,
dyspnea, fever,
anorexia

#7

hypoxemic
respiratory
failure, ARDS,
encephalopathy
,
unresponsivene
ss

None

None

None

None

Myalgias,
cough,
dyspnea, fever,
anorexia on
presentation

Hypoxemic
respiratory
failure, ARDS,
encephalopathy
,
unresponsivene
ss on
presentation
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Sinus
pauses up
to 17
seconds
and sinus
arrest
requiring
rescucitatio
n (29)

Semipermanent
pacemaker
implant
(29)

Death (30)

Sinus pause
of 36
seconds
and new
RBBB with
right axis
deviation
(4)

Leadless
pacemaker
implant (5)

Death (7)

